Auph short interest.

Short Interest. Percentage of Shares Shorted 11.97% of the outstanding shares of Aurinia Pharmaceuticals have been sold short. Short Interest Ratio / Days to …Zhanna Hapanovich/iStock via Getty Images. Aurinia Pharmaceuticals (NASDAQ:AUPH) plunged 14% after the company announced Thursday three new executive hires, including a new R&D chief, likely cooling speculation that the company may be acquired.Aurinia also disclosed that its chief commercial officer will be leaving next …AUPH Earnings Date and Information. Aurinia Pharmaceuticals last issued its quarterly earnings data on November 2nd, 2023. The biotechnology company reported ($0.09) EPS for the quarter, topping analysts' consensus estimates of ($0.17) by $0.08. The company had revenue of $54.52 million for the quarter, compared to the consensus estimate of $38 ...AUPH has a market cap of $1.08bn and $400 million of cash, cash equivalents, restricted cash and investments as of October 31, 2022. In the previous quarter, the company made $55mn in revenue ...

Aurinia Pharmaceuticals Reports First Quarter 2023 Financial and Operational Results Business Wire - Thu May 4, 5:00AM CDT. Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today issued its financial results for first quarter ended March 31, 2023. Amounts are expressed in U.S. dollars. 9.28.

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH – Get Rating) (TSE:AUP) was the recipient of a large decline in short interest during the month of November. As of November 15th, there was short interest totalling 8,290,000 shares, a decline of 27.7% from the October 31st total of 11,460,000 shares.Web

Auph only had 1 month of sales last quarter, due to insurance companys taking 20 to 50 days to approve each patient...thats the reason for sales short fall Reply Like (7) dMeanwhile, Jefferies analyst Maury Raycroft, with a Buy rating on Aurinia ( AUPH ), has cut the per share target to $29 from $34 to imply a premium of ~142% to the last close. Raycroft attributes ...Sep 21, 2023 · Aurinia Pharmaceuticals ( NASDAQ: AUPH) named Dr. Robert Foster as a new board member Thursday as part of an agreement with its major shareholder and investment management firm, MKT Capital Ltd ... Aurinia Pharmaceuticals AUPH closed the last trading session at $9.04, gaining 22.8% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $13.21 indicates a 46.1% upside potential. The average comprises seven short-term …A high-level overview of Aurinia Pharmaceuticals Inc. (AUPH) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and …

Short Squeeze - Canada; Short Squeeze - Hong Kong; Highest Cost to Borrow; Highest Short Float; Owners Retail Ownership Most Popular Funds Activist Investors Fund Sentiment - World. United States Canada UK Hong Kong Japan Australia New Zealand. Germany Switzerland Spain Poland Netherlands Greece France Ireland Italy Belgium …Web

AUPH Short Positions, Funds Shorting Aurinia Pharmaceuticals Inc ... Short Interest Funds Shorting AUPH Short Transactions Short Volume Fails to Deliver. Options . Options Chain Options Sentiment Options Flow Gamma Exposure Implied Volatility. Filings . SEC Filings - Categorized SEC Filings - Latest Press Releases Exhibits. Financials .

AUPH short interest is 8.5%. Also see, Alnylam Pharma is said to be a potential target for Novartis. Recommended For You. Comments (34) Newest. Publish. Have a tip? Submit confidentially to our ...E131: 2024 Fantasy President picks, debt ceiling agreement, Dollar dominance & moreWebIf you stay in your home long enough, you usually build enough equity that you can sell it for a profit. When you have to sell the property before then or during a downturn in the market, you may need to find out how to short sale a house.BBBY short interest is up more than 17.5m shares. r/Shortsqueeze • Bed Bath and to infinity and Beyond - Why BBBY is legitimately the closest play to GME & AMCBack to AUPH Overview. NASDAQ, Inc. short interest is available by issuer for the past 12 months and updated twice a month. Short interest data is reported on …Aurinia Pharmaceuticals Reports First Quarter 2023 Financial and Operational Results Business Wire - Thu May 4, 5:00AM CDT. Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today issued its financial results for first quarter ended March 31, 2023. Amounts are expressed in U.S. dollars. 9.28.

According to the issued ratings of 2 analysts in the last year, the consensus rating for Aurinia Pharmaceuticals stock is Buy based on the current 2 buy ratings for AUPH. The average twelve-month price prediction for Aurinia Pharmaceuticals is $14.00 with a high price target of $15.00 and a low price target of $13.00.Aurinia Pharmaceuticals Inc. is a late stage biopharmaceutical company. It focuses on the development of therapeutic immunomodulating drug candidate. The company's lead drug includes Voclosporin ...Jul 4, 2022 · Still, when we talk about a small-cap biotech that is clearly drawing the interest of some big pharma guys, we can say that AUPH's current valuation is very low, without but surely with buyout ... A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. DAWN shares currently have a short interest ratio of 15.0. Learn More on Day One Biopharmaceuticals's short interest ratio.Aurinia Pharma press release (NASDAQ:AUPH): Q2 GAAP EPS of -$0.08 beats by $0.11.; Revenue of $41.49M (+47.2% Y/Y) beats by $3.98M. Increases 2023 revenue guidance range to $150 - $160 million ...Data Link's cloud-based technology platform allows you to search, discover and access data and analytics for seamless integration via cloud APIs. Register for your free account today at data ...Mar 21, 2023 · Biotech stocks are very interest rate sensitive and I suspect once the Federal Reserve pivots and begins cutting interest rates, AUPH and the rest of the sector's stocks will move materially ...

Amneal Pharmaceuticals saw a increase in short interest in November. As of November 15th, there was short interest totaling 3,620,000 shares, an increase of 13.5% from the previous total of 3,190,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are …Web

Loan debt generally consists of two parts: the principal, or the total amount of the loan, and interest, or the extra amount the lender charges as compensation for what you’ve borrowed.2023-03-10 Short sale volume (not short interest) for $AUPH is 38%. http://shortvolumes.com/?t=AUPH $AEZS 37% $REGN 56% $XLV 46%. 11 Mar 2023 12:54:01WebAmount of cash a business has after it has met its financial obligations such as debt and outstanding payments. -25.98M. -347.29%. Get the latest Ardelyx Inc (ARDX) real-time quote, historical ...WebAurinia ( AUPH) shares have climbed ~59.7% in the year so far despite a ~2% decline over the past 30 days. The stock has added ~5.8% in the post-market with ~1.5M shares changing hands compared to ...Some thoughts on AUPH: 1. As cited, AUPH reported Lupkynis sales +46% YOY, +20% over Q1, and raised full year guidance to $150 million - $160 million, but admittedly is only scratching the surface ...Aurinia Pharma press release (NASDAQ:AUPH): Q3 GAAP EPS of -$0.09 beats by $0.08.; Revenue of $54.52M (-2.3% Y/Y) beats by $16.02M. Achieved European pricing and reimbursement milestone triggering ...Aurinia Pharmaceuticals ( NASDAQ: AUPH) rose 6.5% amid renewed takeover speculation. There's speculation than unnamed suitor may be eyeing a takeover of Aurinia ( AUPH ), according to a Betaville ...Short interest is the volume of POINT Biopharma Global shares that have been sold short but have not yet been covered or closed out. As of October 31st, traders have sold 4,390,000 shares of PNT short. 5.09% of POINT Biopharma Global's shares are currently sold short. Learn More on POINT Biopharma Global's current short interest.AUPH Short Interest Back to AUPH Overview NASDAQ, Inc. short interest is available by issuer for the past 12 months and updated twice a month. Short interest data is reported on...Back to AUPH Overview. NASDAQ, Inc. short interest is available by issuer for the past 12 months and updated twice a month. Short interest data is reported on …

Aurinia Pharmaceuticals (AUPH +4.4%) is trading higher after its Chief Executive Officer Peter Greenleaf hinted at strong sales for the company as the management prepares to release the financials ...

Jul 4, 2022 · Still, when we talk about a small-cap biotech that is clearly drawing the interest of some big pharma guys, we can say that AUPH's current valuation is very low, without but surely with buyout ...

Short interest, stock short squeeze, short interest ratio & short selling data positions for NASDAQ, NYSE & AMEX stocks to find shorts in the stock market.WebAurinia Pharmaceuticals (AUPH +4.4%) is trading higher after its Chief Executive Officer Peter Greenleaf hinted at strong sales for the company as the management prepares to release the financials ...The u/AnalystRipper community on Reddit. Reddit gives you the best of the internet in one place.2021-12-27 Short sale volume (not short interest) for $JMIA is 33%. http://shortvolumes.com/?t=JMIA $ERIC 56% $SOS 58% $AUPH 42% $QLGN 52%. 28 Dec 2021WebThese cookies may be set through our site by us and our advertising partners to make advertising messages more relevant to you. They perform functions like preventing the same ad from continuously reappearing, ensuring that ads are properly displayed for advertisers, selecting advertisements that are based on your interests and measuring the number of …Artal Group S.A. increased its stake in shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR – Get Rating) by 33.3% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,000,000 shares of the company’s stock after buying an additional 500,000 …WebNov 21, 2023 · Aurinia Pharmaceuticals ( NASDAQ: AUPH) soared 6.7% amid takeover speculation. The Aurinia ( AUPH) stock surge comes amid a report that a Gilead Sciences ( GILD) corporate jet made a trip to ... If you have a small frame and are looking for the perfect short haircut, you’ve come to the right place. Choosing the right haircut for your small frame can be tricky, but with the right tips and advice, you can find a style that looks grea...Aug 2, 2023 · Aurinia Pharma (AUPH) is scheduled to announce Q2 earnings results on Thursday, August 3rd, before market open.The consensus EPS Estimate is -$0.18 (+28.0% Y/Y) and the consensus...

Aurinia Pharmaceuticals Stock (NASDAQ:AUPH), Short Interest Report. Short interest for Aurinia Pharmaceuticals gives investors a sense of the degree to …Mar 24, 2023 · AUPH has a market cap of $1.3bn and a cash balance of $389mn. Research and development expenses were USD 9.9 million for 4Q. Selling, general and administrative expenses, inclusive of share-based ... Dec 2, 2021 · Aurinia Pharmaceuticals (AUPH) rose 17% at least partly on some take takeover speculation following comments from Novartis (NVS). Novartis reportedly said during its R&D day earlier... Instagram:https://instagram. texas pacific land trust stockhighest risk investmentexxon dividend yieldoil refineries in usa In the most recent earnings period of Q1 of 2023, Aurinia Pharmaceuticals Inc. reported 59% year-over-year growth in revenue of LUPKYNIS™ to $34.4 million. Full-year 2023 revenue guidance range ...Business, Economics, and Finance. GameStop Moderna Pfizer Johnson & Johnson AstraZeneca Walgreens Best Buy Novavax SpaceX Tesla. Crypto dental plans pennsylvaniabest book for stock market Track Aurinia Pharmaceuticals Inc (AUPH) Stock Price, Quote, latest community messages, chart, news and other stock related information. Share your ideas and get valuable insights from the community of like minded traders and investors bmi calculator mayo clinic HRTX 1.3100 (+20.18%) Aurinia Pharmaceuticals Reports First Quarter 2023 Financial and Operational Results Business Wire - Thu May 4, 5:00AM CDT. Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today issued its financial results for first quarter ended March 31, 2023. Amounts are expressed in U.S. dollars.Historical equity short-Interest data for all listed tickers starting 2018 ... AUPH (Aurinia Pharmaceuticals Inc) Start Date:2013-11-08. AUR (Aurora Innovation ...Feb 28, 2022 · For 2022, Aurinia ( AUPH) projects net revenue from sales of Lupkynis to reach $115M-135M. Several days ago, shares of the company surged in reaction to upbeat remarks made by CEO on its sales ...